{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:04:22Z","timestamp":1790269462656,"version":"4.1.0"},"reference-count":111,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/17474086.2019.1647778","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T06:54:06Z","timestamp":1564383246000},"page":"893-908","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Novel therapies in low- and high-risk myelodysplastic syndrome"],"prefix":"10.1080","volume":"12","author":[{"given":"Ulrich","family":"Germing","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kaivers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"K\u00fcndgen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"issue":"46","key":"e_1_3_4_3_1","first-page":"783","article-title":"Myelodysplastic syndromes: diagnosis, prognosis, and treatment","volume":"110","author":"Germing U","year":"2013","unstructured":"Germing U, Kobbe G, Haas R, et al. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int. 2013 15;110(46):783\u2013790.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.06.001"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.04.001"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.10.013"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2649-3"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24704"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01299.x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.391"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0007"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu180"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-492884"},{"key":"e_1_3_4_16_1","unstructured":"Hofmann WK Platzbecker U G\u00f6tze K et al. Myelodysplastic syndromes guidelines of the German Austrian and Suisse societies of hematology. 2018. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/myelodysplastische-syndrome-mds\/@@view\/html\/index.html"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.340"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0118-9"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.192"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4013211.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512442"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12579"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3137-0"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24842"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12679"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S172306"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01299.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28663"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30016-4"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399667"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30012-1"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-855221"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2367-1"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1222"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.048546"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12300"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14825"},{"key":"e_1_3_4_38_1","unstructured":"Hoeks M. Impact of treatment with iron chelators in lower-risk MDS patients participating in the European LeukemiaNet MDS (EUMDS) Registry. ASH 2017 abstract 425."},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","unstructured":"Angelucci E Li J Greenberg PL et al. Safety and efficacy including event-free survival of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized double-blind Telesto study. Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA. Abstract 234.","DOI":"10.1182\/blood-2018-99-111134"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22299"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13096"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019414"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402894"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.305"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.523"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.0118"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.268"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2983-0"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-068833"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.12.012"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.296"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.111"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-016-0049-5"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.265"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2933"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30615-0"},{"key":"e_1_3_4_57_1","unstructured":"Fenaux P Platzbecker U Mufti G et al.. Results of a phase 3 randomized double-blind placebo-controlled study of luspatercept to treat anemia in patients with very low- low- or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require Red Blood Cell (RBC) transfusions. Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30002-4"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.03.007"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86621"},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","unstructured":"Steensma D Platzbecker U van Koen E et al. Imetelstat treatment leads to durable transfusion independence in RBC transfusion-dependent non-del(5q) lower-risk MDS relapsed\/refractory to erythropoiesis-stimulating agent who are lenalidomide and HMA na\u00efve. Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA.","DOI":"10.1182\/blood-2018-99-114877"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.21"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.227.227"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.180"},{"key":"e_1_3_4_65_1","unstructured":"Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients with Lower-risk MDS with Low Red Blood Cell Transfusion Burden. NCT-Number: NCT03263091. www.clinicaltrials.gov"},{"key":"e_1_3_4_66_1","unstructured":"A Phase 1 Study to Evaluate H3B-8800 in Participants with Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02841540"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3466-7"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.115"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25328"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30949"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13148-011-0031-9"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29083"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13016"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.26"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00026-X"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"e_1_3_4_77_1","doi-asserted-by":"crossref","unstructured":"Ades L Guerci A Laribi K et al. A randomized phase ii study of azacitidine (AZA) Alone or with Lenalidomide (LEN) Valproic Acid (VPA) or Idarubicin (IDA) in higher-risk MDS: gfm\u2019s \u2018pick a winner\u2019 trial. Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA.","DOI":"10.1182\/blood-2018-99-111756"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30533"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-805895"},{"key":"e_1_3_4_81_1","doi-asserted-by":"crossref","unstructured":"Vey N. Addition of the SMO inhibitor sonidegib to azacitidine in patients with higher-risk myelodysplastic syndrome (MDS) who failed to respond or lost response to AZA alone: results of a phase 1-2 add-on study by the GFM. Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA.","DOI":"10.1182\/blood-2018-99-113529"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13323"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00038-8"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30576-4"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31138"},{"key":"e_1_3_4_86_1","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G Ritchie EK Walsh KJ et al. Long term results of a randomized phase 2 dose-response study of guadecitabine a novel Subcutaneous (SC) Hypomethylating Agent (HMA) in 102 Patients with intermediate or high risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA.","DOI":"10.1182\/blood-2018-99-110465"},{"key":"e_1_3_4_87_1","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G Sasaki K Montalban-Bravo G et al. Final report of a phase ii study of guadecitabine (SGI-110) in Patients (pts) with previously untreated myelodysplastic syndrome (MDS). Abstract Presented at the 2018 ASH Annual Meeting; 2018; San Diego CA.","DOI":"10.1182\/blood-2018-99-116838"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.275"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00009-7"},{"key":"e_1_3_4_92_1","doi-asserted-by":"crossref","unstructured":"Daver N Garcia-Manero G Basu S et al. Efficacy safety and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a non-randomized open-label phase 2 study. Cancer Discov. 2019 Mar;9(3):370\u2013383.","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3324"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355"},{"issue":"2018","key":"e_1_3_4_95_1","first-page":"2458679","article-title":"The rising era of immune checkpoint inhibitors in myelodysplastic syndromes","volume":"1","author":"Chokr N","year":"2018","unstructured":"Chokr N, Patel R, Wattamwar K, et al. The rising era of immune checkpoint inhibitors in myelodysplastic syndromes. Adv Hematol. 2018 Nov;1(2018):2458679.","journal-title":"Adv Hematol"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3763"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119424"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115720"},{"issue":"1","key":"e_1_3_4_99_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2018-99-118577","article-title":"PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis","volume":"132","author":"Gerds AT","year":"2018","unstructured":"Gerds AT, Scott BL, Greenberg PL, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis. Blood. 2018;132(Suppl 1):466.","journal-title":"Blood"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.179"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24775"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.910657"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1452611"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.016"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3185-5"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168716"},{"key":"e_1_3_4_113_1","doi-asserted-by":"crossref","unstructured":"Schroeder T Rautenberg C Christopeit M et al. Treatment of MDS AML and CMML relapse after allogeneic blood stem cell transplantation with azacitidine lenalidomide and donor lymphocyte infusions \u00e2\u20ac\u201c results from the second interim analysis of the prospective azalena-trial (NCT02472691). Abstract Presented at the 2018 ASH Annual Meeting 2018; San Diego CA","DOI":"10.1182\/blood-2018-99-113776"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2019.1647778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:38:18Z","timestamp":1772732298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2019.1647778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/17474086.2019.1647778"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2019.1647778","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}